Bucillamine
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 315351

CAS#: 65002-17-7

Description: Bucillamine is an antirheumatic agent developed from tiopronin. It is mainly used in Japan and Korea. Activity is mediated by the two thiol groups that the molecule contains. Research done in USA showed positive transplant preservation properties.


Chemical Structure

img
Bucillamine
CAS# 65002-17-7

Theoretical Analysis

MedKoo Cat#: 315351
Name: Bucillamine
CAS#: 65002-17-7
Chemical Formula: C7H13NO3S2
Exact Mass: 223.03368
Molecular Weight: 223.31
Elemental Analysis: C, 37.65; H, 5.87; N, 6.27; O, 21.49; S, 28.72

Size Price Shipping out time Quantity
10mg USD 90 2 Weeks
20mg USD 150 2 Weeks
50mg USD 250 2 Weeks
100mg USD 450 2 Weeks
200mg USD 650 2 Weeks
500mg USD 950 2 Weeks
1g USD 1450 2 Weeks
2g USD 1950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-03-02. Prices are subject to change without notice.

Bucillamine, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Related CAS #: 82017-48-9 (disuflide)  

Synonym: Bucillamine; DE-019; DE 019; DE019; SA96; Thiobutarit; Tiobutarit; Rimatil.

IUPAC/Chemical Name: 3-mercapto-2-(2-mercapto-2-methylpropanamido)propanoic acid

InChi Key: VUAFHZCUKUDDBC-UHFFFAOYSA-N

InChi Code: InChI=1S/C7H13NO3S2/c1-7(2,13)6(11)8-4(3-12)5(9)10/h4,12-13H,3H2,1-2H3,(H,8,11)(H,9,10)

SMILES Code: O=C(O)C(NC(C(C)(S)C)=O)CS

Appearance:
solid powder

Purity:
>97% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 223.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Matsuno H, Okada M, Sakai Y, Abe C, Katayama K, Sagawa A, Yamasaki K, Kondo M, Funahashi K, Matsubara T. The Usefulness of a New Triple Combination Treatment Utilizing methotrexate, salazosulfapyridine, and bucillamine in Rheumatoid Arthritis. Mod Rheumatol. 2015 Jun 8:1-20. [Epub ahead of print] PubMed PMID: 26052803.

2: Manabe S, Banno M, Nakano M, Fujii T, Fujiwara M, Kita Y, Nitta K, Hatano M. Bucillamine-induced membranous nephropathy with crescent formation in a patient with rheumatoid arthritis: case report and literature review. Case Rep Nephrol Dial. 2014 Oct 29;5(1):30-8. doi: 10.1159/000368826. eCollection 2015 Jan-Apr. PubMed PMID: 25849672; PubMed Central PMCID: PMC4294451.

3: Kim SJ, Ho Hur J, Park C, Kim HJ, Oh GS, Lee JN, Yoo SJ, Choe SK, So HS, Lim DJ, Moon SK, Park R. Bucillamine prevents cisplatin-induced ototoxicity through induction of glutathione and antioxidant genes. Exp Mol Med. 2015 Feb 20;47:e142. doi: 10.1038/emm.2014.112. PubMed PMID: 25697147; PubMed Central PMCID: PMC4346486.

4: Katayama K, Okubo T, Sato T, Ito H, Fukai R, Baba H. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice. Mod Rheumatol. 2015 Jan;25(1):50-5. doi: 10.3109/14397595.2014.924385. Epub 2014 Jul 1. PubMed PMID: 24983407.

5: Furukawa H, Oka S, Shimada K, Sugii S, Hashimoto A, Komiya A, Fukui N, Miyashita T, Migita K, Suda A, Nagaoka S, Tsuchiya N, Tohma S. HLA-DRB1*08:02 Is Associated with Bucillamine-Induced Proteinuria in Japanese Rheumatoid Arthritis Patients. Biomark Insights. 2014 May 19;9:23-8. doi: 10.4137/BMI.S13654. eCollection 2014. PubMed PMID: 24899791; PubMed Central PMCID: PMC4038630.

6: Yanagishita T, Tamada Y, Watanabe D. Bucillamine-induced pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1242-3. doi: 10.1111/jdv.12472. Epub 2014 Mar 18. PubMed PMID: 24641261.

7: Dahboul F, Perrin-Sarrado C, Boudier A, Lartaud I, Schneider R, Leroy P. S,S'-dinitrosobucillamine, a new nitric oxide donor, induces a better vasorelaxation than other S-nitrosothiols. Eur J Pharmacol. 2014 May 5;730:171-9. doi: 10.1016/j.ejphar.2014.02.034. Epub 2014 Mar 10. PubMed PMID: 24625595.

8: Yoshimura K, Ishii N, Hamada T, Abe T, Ono F, Hashikawa K, Fukuda S, Ohyama B, Koga H, Sogame R, Teye K, Ochiai T, Nakajima H, Nakajima K, Iijima S, Kanzaki M, Kojima K, Nagatani T, Fujimoto W, Karashima T, Nakama T, Ohata C, Furumura M, Tsuruta D, Hashimoto T. Clinical and immunological profiles in 17 Japanese patients with drug-induced pemphigus studied at Kurume University. Br J Dermatol. 2014 Sep;171(3):544-53. doi: 10.1111/bjd.12925. Epub 2014 Aug 27. PubMed PMID: 24588203.

9: Kurasawa T, Nagasawa H, Kishimoto M, Amano K, Takeuchi T, Kameda H. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial. Mod Rheumatol. 2014 Jul;24(4):561-6. doi: 10.3109/14397595.2013.844886. Epub 2013 Nov 5. PubMed PMID: 24252035.

10: Tanaka E, Yamanaka H. [DMARDs (disease-modifying antirheumatic drugs)]. Nihon Rinsho. 2013 Jul;71(7):1199-206. Review. Japanese. PubMed PMID: 23961667.